Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options

Rhea-AI Summary

Humana Specialty Pharmacy announced the addition of two oncology therapies: TAGRISSO® (osimertinib) for EGFRm non-small cell lung cancer and LENVIMA® (lenvatinib) for various cancers. These drugs will be delivered directly to patients, supported by Humana's Oncology Center of Excellence, which offers expert guidance on treatment. Humana is dedicated to enhancing patient experiences and health outcomes while managing chronic and complex illnesses through personalized services.

Positive

• Introduced two new oncology therapies to enhance treatment options for patients.
• Supports patients with dedicated services through the Oncology Center of Excellence.

Negative

• None.

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Humana Specialty Pharmacy has announced two significant additions to its comprehensive, personalized and targeted oncology therapies.

Patients can now receive the following drugs, delivered to their front doors in a fast and meaningful way, while Humana Specialty Pharmacy supports them along their journey:

• TAGRISSO® (osimertinib), a drug that helps certain patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) manage their disease.
• LENVIMA® (lenvatinib), a drug that helps patients with different forms of cancer, including certain types of thyroid, liver and kidney cancers.

Patients who receive TAGRISSO and LENVIMA from Humana Specialty Pharmacy also benefit from its Oncology Center of Excellence where Humana Specialty Pharmacy patient advocates and specialty pharmacists are available to provide invaluable treatment guidance, including help with managing daily symptoms, assistance on how and when to take medications, and any other questions they may have with respect to staying on their therapy.

“We are honored to be able to dispense these therapies and offer differentiated service and experience to patients through our Oncology Center of Excellence,” said Natalie Bedford, SVP, Humana Specialty Pharmacy. “At Humana Specialty Pharmacy, we are committed to providing a holistic and personal health care experience for all of the patients we serve, to drive overall better health outcomes.”

Humana Specialty Pharmacy, a part of Humana Pharmacy, manages therapies for chronic and complex illnesses while providing patients with both clinical and educational services customized to their individual needs and treatment goals.

More information about Humana Specialty Pharmacy can be found here.

About Humana
Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.

To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools – such as in-home care, behavioral health, pharmacy services, data analytics and wellness solutions – combine to produce a simplified experience that makes health care easier to navigate and more effective.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at www.humana.com, including copies of:

• Annual reports to stockholders
• Securities and Exchange Commission filings
• Most recent investor conference presentations
• Quarterly earnings news releases and conference calls
• Calendar of events
• Corporate Governance information

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005470/en/

Lisa Dimond

Humana Corporate Communications

832-330-4702

ldimond@humana.com

Source: Humana Inc.

FAQ

What new oncology therapies has Humana introduced?

Humana has introduced TAGRISSO® (osimertinib) and LENVIMA® (lenvatinib) for cancer treatment.

How does Humana support patients receiving TAGRISSO and LENVIMA?

Humana supports patients through its Oncology Center of Excellence, providing treatment guidance and assistance.

What is Humana's stock symbol?

Humana's stock symbol is HUM.

When was the announcement about new therapies made?

The announcement regarding the new therapies was made on February 8, 2022.